| Dr William H Stonehill, MD | |
|
2326 18th St Ste 230, Columbus, IN 47201-5359 | |
| (812) 376-9261 | |
| (812) 378-9518 |
| Full Name | Dr William H Stonehill |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 34 Years |
| Location | 2326 18th St Ste 230, Columbus, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427053511 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 01044905 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Columbus Regional Hospital | Columbus, IN | Hospital |
| King's Daughters' Health | Madison, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Columbus Regional Health Physicians Llc | 1052612314 | 192 |
News Archive
A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.
The leaders of a bipartisan congressional committee charged with finding at least $1.2 trillion in deficit reduction over the next decade say Americans' confidence in Washington hinges on their success. … If the committee deadlocks or fails, $1.2 trillion still would be cut automatically from future deficits, divided between defense and domestic spending, including Medicare. Hensarling likened that threat to "a hammer in the closet".
Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 3 days ago
| Entity Name | Allied Physicians Of Michiana, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508191768 PECOS PAC ID: 4486627601 Enrollment ID: O20091216000468 |
News Archive
A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.
The leaders of a bipartisan congressional committee charged with finding at least $1.2 trillion in deficit reduction over the next decade say Americans' confidence in Washington hinges on their success. … If the committee deadlocks or fails, $1.2 trillion still would be cut automatically from future deficits, divided between defense and domestic spending, including Medicare. Hensarling likened that threat to "a hammer in the closet".
Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 3 days ago
| Entity Name | Columbus Regional Health Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336510098 PECOS PAC ID: 1052612314 Enrollment ID: O20151211000054 |
News Archive
A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.
The leaders of a bipartisan congressional committee charged with finding at least $1.2 trillion in deficit reduction over the next decade say Americans' confidence in Washington hinges on their success. … If the committee deadlocks or fails, $1.2 trillion still would be cut automatically from future deficits, divided between defense and domestic spending, including Medicare. Hensarling likened that threat to "a hammer in the closet".
Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William H Stonehill, MD Po Box 775383, Chicago, IL 60677-5383 Ph: (812) 376-5315 | Dr William H Stonehill, MD 2326 18th St Ste 230, Columbus, IN 47201-5359 Ph: (812) 376-9261 |
News Archive
A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.
The leaders of a bipartisan congressional committee charged with finding at least $1.2 trillion in deficit reduction over the next decade say Americans' confidence in Washington hinges on their success. … If the committee deadlocks or fails, $1.2 trillion still would be cut automatically from future deficits, divided between defense and domestic spending, including Medicare. Hensarling likened that threat to "a hammer in the closet".
Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 3 days ago
Dana Stuart Pfaff, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2475 North Park Ste 10, Columbus, IN 47203 Phone: 812-376-9261 Fax: 812-378-9518 | |
Ryan William Zipper, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2326 18th St Ste 230, Columbus, IN 47201 Phone: 812-376-9261 | |
Karl J Mcaleese, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2475 N Park Dr, Ste 10, Columbus, IN 47203 Phone: 812-376-9261 Fax: 812-378-9518 | |
Dr. John Joseph Francis, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2326 18th St Ste 230, Columbus, IN 47201 Phone: 812-376-9261 Fax: 812-378-9518 |